Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
C16 Biosciences Inc. currently has 2 pending office actions in the Chemistry & Materials technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units, indicating that the portfolio's active cases are being reviewed in different technical environments. ASSAF ZILBERING is the busiest examiner, currently managing 1 busiest examiner pending action.
The 2 pending office actions are distributed such that the 2 distinct examiners each handle a portion of the workload. With 2 distinct art units involved, the company must address the specific requirements of 2 different USPTO groups. ASSAF ZILBERING's role as the busiest examiner with 1 busiest examiner pending action highlights that the workload is shared across the 2 distinct examiners. This structure suggests that the 2 pending office actions are not concentrated under the authority of 1 individual. For a company in Chemistry & Materials, navigating 2 distinct art units requires a versatile approach to prosecution, as each unit may have different interpretations of prior art or patentability.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZILBERING, ASSAF | 1 | 35.2% | +27.8% |
| HAWKINS, AMANDA SALATA | 1 | 12.0% | +45.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035594 | EDIBLE MICROBIAL OIL | ZILBERING, ASSAF | 34d |
| 17885280 | MICROBIALLY PRODUCED PALM OIL SUBSTITUTES | HAWKINS, AMANDA SALATA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035594 | EDIBLE MICROBIAL OIL | ZILBERING, ASSAF | 34d |
| 17885280 | MICROBIALLY PRODUCED PALM OIL SUBSTITUTES | HAWKINS, AMANDA SALATA | — |
| Art Unit | Apps |
|---|---|
| 1792 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18035594 | EDIBLE MICROBIAL OIL | ZILBERING, ASSAF | 1792 | §102§103 | Non-Final OA | 34d | Pending | May 05, 2023 |
| 17885280 | MICROBIALLY PRODUCED PALM OIL SUBSTITUTES | HAWKINS, AMANDA SALATA | 1793 | §103 | Non-Final OA | — | Pending | Aug 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial